Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.

about

Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab.

Item

http://www.wikidata.org/entity/Q38632525

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Improvements in psoriasis with ...... ing treatment with ixekizumab.

@en

type

Item

label

Improvements in psoriasis with ...... ing treatment with ixekizumab.

@en

prefLabel

Improvements in psoriasis with ...... ing treatment with ixekizumab.

@en

P1476

Improvements in psoriasis with ...... ing treatment with ixekizumab.

@en

P2093

Andrew Blauvelt

http://www.w3.org/2001/XMLSchema#string

Craig H Mallinckrodt

http://www.w3.org/2001/XMLSchema#string

Jeffrey J Crowley

http://www.w3.org/2001/XMLSchema#string

Kyoungah See

http://www.w3.org/2001/XMLSchema#string

Peter van de Kerkhof

http://www.w3.org/2001/XMLSchema#string

Talia M Muram

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.

Psoriasis assessment tools in clinical trials.

The cutaneous vascular system in chronic skin inflammation

Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab.

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis.

Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A.

British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009.

Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.

P304

1-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/09546634.2017.1365114

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28792259

http://www.w3.org/2001/XMLSchema#string